160357-91-5

Usage

Molecular Structure

A piperidine ring with a pyridine and an amine group attached to it

Usage

Commonly used in pharmaceutical research and drug development

Potential Applications

Treatment of various diseases and conditions, including neurological disorders, mental health conditions, pain management, and inflammation

Role

Building block for creating new compounds with therapeutic properties

Importance

Unique structure and molecular properties make it a valuable tool in drug discovery and medicinal chemistry

Future Prospects

Potential for further research and development in the field of drug discovery and medicinal chemistry

InChI:InChI=1/C11H17N3/c12-10-4-7-14(8-5-10)9-11-3-1-2-6-13-11/h1-3,6,10H,4-5,7-9,12H2

Downstream Products

• 252578-07-7 3-[1-(Pyrid-2-yl-Methyl)4-Piperidinylamino]-1-(4-Hydroxy-Phenoxy)-2-Propanol 

Relevant academic research and scientific papers

6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines

The present invention provides novel compounds of the formula (I) wherein R is selected from the group consisting of R2, R2NH—, or R3R4N—R5- wherein R2 is selected from the group consisting of C9-C12alkyl, Z is selected from the group consisting of phenyl, heterocycle, cycloalkyl, and naphthanlene; and M is selected from the group consisting of hydrogen, C1-C4alkyl, and wherein each C9-C12alkyl or Z is optionally substituted with 1 to 3 substituents, which may be the same or different, and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, and C1-C4alkoxy; each E is independently selected from the group consisting of Hal, OH, and C1-C8alkyl; R3 and R4 are selected from the group consisting of hydrogen, C1-C4alkyl and (CH2)y-phenyl, wherein y is an integer 0-8, with the proviso that R3 and R4 not both be hydrogen; R5 is C1-C8alkylene; and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers, and hydrates thereof, with the proviso that when R2 is the group wherein n is 1 or greater; R1 is isopropyl or cyclopentyl; R6 is hydrogen, C1-C4alkyl, or (CH2)m-phenyl; and Z is phenyl, heterocycle, or cycloalkyl, that Z is substituted with 1 to 3 substituents, which may be the same or different, and which are selected from the group consisting of In addition, the present invention provides a method of inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.